Brainstorm Cell Therapeutics (STU:GHDN) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Brainstorm Cell Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Brainstorm Cell Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was €-2.82 Mil. Brainstorm Cell Therapeutics's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Brainstorm Cell Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Brainstorm Cell Therapeutics's current FCF Yield % is -63.86%.

The historical rank and industry rank for Brainstorm Cell Therapeutics's FCF Margin % or its related term are showing as below:

STU:GHDN's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.31
* Ranked among companies with meaningful FCF Margin % only.

Brainstorm Cell Therapeutics FCF Margin % Historical Data

The historical data trend for Brainstorm Cell Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics FCF Margin % Chart

Brainstorm Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Brainstorm Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Brainstorm Cell Therapeutics's FCF Margin %

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's FCF Margin % falls into.

Brainstorm Cell Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Brainstorm Cell Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-18.777	/	0
	=	%

Brainstorm Cell Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.818	/	0
	=	%

Brainstorm Cell Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Brainstorm Cell Therapeutics (STU:GHDN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (STU:GHDN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BCLI:USA GHDN:Germany

Address

1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019

Website

https://www.brainstorm-cell.com

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (STU:GHDN) Headlines

No Headlines